YUVEZZI is the only dual-agent eye drop for presbyopia1
Unlike single-agent miotics, the 2 ingredients in YUVEZZI work together to deliver consistent and durable pupil modulation1
Carbachol 2.75%
Carbachol is a cholinergic agonist that1
Acts directly on the iris sphincter to constrict the pupil, creating a pinhole effect- Improves depth of focus and near visual acuity, with less impact on the ciliary muscle
Brimonidine tartrate 0.1%
Brimonidine tartrate is an α-adrenergic agonist that1
Blocks contraction of the iris dilator muscle, helping maintain a functional pupil size- Relaxes tonic contraction of the ciliary muscle
- Increases aqueous humor bioavailability of carbachol, prolonging its effect in the anterior chamber
See how YUVEZZI works
Presbyopia occurs when the ocular lens fails to accommodate when shifting from far to near vision, resulting in inability to focus on near objects. When the lens' capacity to accommodate is reduced with time, pupillary constriction can help achieve visual acuity by redirecting the light that comes into the eye, creating a pinhole effect that allows for an increased depth of field, facilitating in-focus vision.
Pupil size is regulated by both iris sphincter and dilator muscles, which have antagonistic effects.
YUVEZZI is the only dual-agent eye drop approved for treatment of presbyopia that harnesses the combined power of carbachol and brimonidine to promote pupillary iris constriction and prevent dilation. Carbachol is a cholinergic agent that activates muscarinic M3 receptors to directly induce pupillary constriction.
Meanwhile, brimonidine selectively activates alpha-2 adrenergic receptors on presynaptic nerve endings reducing the release of norepinephrine, blocking dilator muscle activation. Together, carbachol and brimonidine induce meiosis to improve visual acuity in people with presbyopia. In addition, brimonidine has been shown to increase carbachol’s aqueous humor, bioavailability and concentration in the anterior chamber, allowing YUVEZZI to maintain its pharmacodynamic effect up to 10 hours.
The mechanism of YUVEZZI allows relaxation of the ciliary muscles tonic contraction and provides enhanced selectivity for the pupil. Firstly, carbachol’s reduced affinity to ciliary receptors allows it to act preferentially on the iris sphincter. Additionally, alpha-2 adrenergic agonism may inhibit ciliary muscle contraction.
With one drop once a day the combined action of carbachol and brimonidine in YUVEZZI induces pupillary reduction to an optimal range and facilitates visual acuity for people with presbyopia.
YUVEZZI achieves miosis from 30 minutes up to 10 hours1
YUVEZZI demonstrated significant and sustained pupil constriction from 0.5 to 10 hours post-dose compared to carbachol or brimonidine alone, and 0.5 to 8 hours post-dose compared to vehicle (P<0.01).1
Modern lifestyles require presbyopia solutions that meet daily and long-term needs5,6
Topical miotics should combine efficacy, tolerability, and convenience5,7
One daily drop provides functional near vision and a maintained pupil size regardless of lighting conditions5,7,8
Tolerability and ease of dosing can impact sustained use among patients5,7
View Patient Types